Background: Ankylosing spondylitis (AS) is a chronic inflammatory disease mainly affecting the spine and sacroiliac joints. Macrophage migration inhibitory (MIF) factor is a regulatory cytokine that inhibits random immune cell migration. MIF gene promoter polymorphisms play a role in the progression of several inflammatory disorders. Aims: To investigate the relationship between the MIF gene -173 G/C single-nucleotide polymorphism (SNP) and AS.
Ankylosing spondylitis (AS) is a chronic inflammatory disease that affects the spine and sacroiliac joints. AS is characterized by sacroiliac joint inflammation, peripheral inflammatory arthropathy and a totally lack or low levels of rheumatoid factor (1, 2) . It influences EXTRA-ARTICULAR organs such as eye, skin and cardiovascular system organs less frequently. The prevalence of AS is about 0.1-1.4% (2) . Most patients develop first symptoms in the second or third decade. Males are effected more frequently than females. AS is strongly associated with human leukocyte antigen B27 (HLA-B27) of the Major Histocompatibility Complex (MHC). First-degree relatives of patients with AS have approximately 10 times greater risk than the general population with HLA-B27-positive in terms of AS progression (3) . The HLA-B27 occurring in 6 % of the US population but more than 90 % of patients with AS. The prevalence of AS in different populations around the world generally correlates with the prevalence of HLA-B27 (4). Although the environment, genes, gender, age and race may be related to this disease, the etiology and pathogenesis of AS remain unknown.
Cytokines are polypeptides that constitute a class of chemical mediator molecule. Macrophage migration inhibitory factor (MIF) is a multipotent molecule that regulates both in inbred and acquired immunity (5) . It is known to be secreted T and B lymphocytes, neutrophils, dendritic cells, monocytes, basophiles and mast cells. MIF gene is localized on chromosome 22q11.2 and composed of 3 exons (6) . It stated that the altered levels of MIF may be play a role in several inflammatory diseases such as rheumatoid arthritis (RA). It is known that the reactive oxygen species (ROS) are effective at the beginning to in inflammatory diseases including AS. Besides, the pro-inflammatory cytokines are responsible for the increased of nitric oxide (NO). MIF take a critical role in the progression of some immune system diseases with the production of NO. But it uncertain the associations between the progression of AS and commonly known oxidative stress markers (7) . Therefore, we think that it should be investigate whether -173 G>C MIF gene polymorphism influence AS pathogenesis. It has been shown that MIF take a considerable role in the progression of inflammatory diseases (6) . Two polymorphisms have been identified in the MIF gene promoter: these a silent polymorphism, -173G>C (rs755622), and a nucleotide repeat polymorphism CATT [5] [6] [7] [8] . These polymorphisms are related to the risk and intensity of the inflammatory disease (5) . Based on these findings, in this study, we investigated the MIF promoter -173 G/C polymorphism in Turkish AS patients. Our study is the first study that analyzes MIF promoter polymorphism in AS.
MATERIALS AND METHODS

Subjects
Macrophage migration inhibitory gene promoter variation was analyzed in 161 AS patients and 194 healthy controls. Subjects included to the study were greater than 18 years. Patients were diagnosed in Physical Medicine and Rehabilitation clinics at our hospital. All patients fulfilled the New York criteria for AS and also, all participants had taken part in our previous study (3) . The majority of AS patients has sacro-iliac involvement. The patients without sacro-iliac symptoms were diagnosed with HLA-B27 positivity and two other symptoms such as hip and other joint involvements. Clinical examinations were performed for all patients. The control group were chosen according to diagnosis criteria of AS. Data collection were performed according to some informations such as age, disease duration, smoking status, exercise habit, peripheral/ extraarticular involvement and several clinical characteristics. Written consent was obtained from all patients and controls before the study, according to the ethical guidelines of the 2008 Declaration of Helsinki and the study was accepted by ethical committee of School of Medicine (13-KAEK-178). Both the groups were of white Caucasian origin, from the Blacksea region of Turkey. Bath Ankylosing spondylitis disease activity index (BASDAI) are the most widely used tools for the assessment of AS functional status and activity. The activity status of patients was evaluated by BASDAI (8) . Clinical and laboratory findings were compared between the groups.
Genotype determination DNA was extracted from 2 mL of venous blood according to Genomic DNA isolation kit procedure (Sigma-Aldrich; Taufkirchen, Germany) and stored at -20°C. The MIF gene genotyped with the PCR based-Restriction Fragment Length Polymorphism (RFLP) technique. The PCR primers were: sense, 5'-ACT-AAG-AAA-GAC CCG-AGG-C-3'; antisense, 5'-GGG-GCA-CGT-TGG-TGT-TTA-C-3'. These were brought to a final volume of 25 μL (9).
DNA was amplified for 30 cycles with denaturation at 95°C, annealing at 60°C and extension at 72°C for 30 cycles (5 min, 45 min, 45 min, 45 sec) and 72°C as for 7 minutes to finish the reaction. Final PCR products were digested in a 30 μL final volume using reaction buffer (2 μl) and Alu enzyme (1 μL) at 37°C 12 hour. The digested fragments were loaded to 2% agarose gel stained with ethidium bromide and visualized using UV transillumination (Quantum-ST4, Vilber Lourmat; Collégien, France).
Statistical analysis
Statistical analyses were performed using SPSS Statistical Package for Social Sciences Version 20.0 (IBM Corp.; Armonk, NY, USA) and the OpenEpi Info software package version 3.01 (10) . The data were given as mean±SD (standard deviation) and (min-max). The allele frequencies and genotype distributions analyzed with chi square (x 2 ) test in patients and control groups. Odds ratio (OR) (OR) and 95% confidence interval (CI) were used for the assessment of risk factors. P values less than 0.05 were considered as significant.
RESULTS
Allele and genotype frequencies of SNPs were calculated and tested for departure from Hardy-Weinberg equilibrium using the Chi-square test. The demographic characteristics of the patients with AS and controls are shown in Table 1 . There was no difference between patients and controls in terms of mean age (p>0.05). The mean age±standard deviation (SD) was 39.92±8.78 and 39.37±10.37 in in patients and control group, respectively. While gender rate was 84 female (52.2%) and 77 male (47.8%) in patient group, in the control group, it was 111 (56.42%) and 83 (42.8%), respectively. Females constituted the majority of cases in both patient and control groups (52.1% and 57.2%) respectively.
The distributions of MIF -173 C/G allele frequencies in patients with AS and controls are given in Table 2 . We found no statistically significant difference in the genotype frequencies of the MIF gene polymorphism in patients and control groups (p>0.05). The MIF gene G allele was 85% in patients and 82.7% in the control group, while the C allele frequency was 15% in patients and 17.3% in the control group. In the combined analysis of the MIF gene, the GG/GC/CC combined genotype was no found to increase the risk of AS compared to the controls. It was found a significant difference between AS patients with homozygous G/G genotype and AS patients with heterozygous G/C and homozygous C/C genotype in terms of the average age and disease duration (p<0.05). Additionally, there was not any difference on patients in terms of diagnosis age, the results of erythrocyte sedimentation rate (ESR) measurements, Schober test measurements, the results of BASDAI (p>0.05) ( Table 3) . We found no association between MIF gene polymorphism and sacroiliac involvement, HLA-B27 positivity, new bone arrangement, ocular involvement, hip involvement, cervical involvement, oral aphthous or familial history (p>0.05) ( Table 4) .
DISCUSSION
Ankylosing spondylitis is associated with chronic inflammation of the sacroiliac and peripheral joints. Although the pathogenesis of AS is not known, genetic factors play a considerable role in its pathogenesis (11) . MIF is an important cytokine as proinflammatory mediator related in the regulation of immunity. Besides, MIF is a key regulator in a variety of biological functions including proinflammatory actions, immunological reactions and carcinogenesis. MIF expression anomalies are effective in the progression of chronic inflammatory diseases. We analyzed whether G/C polymorphism at the MIF gene promoter predisposes to AS disease in this paper. Also, this study is the first report to evaluate the MIF gene polymorphism among AS patients. Because of its relationship with inflammation, the MIF gene and its polymorphisms have been investigated in association with inflammatory rheumatic diseases. The MIF-173 C allele is obviously related to the disease as a result of their study that has been conducted with juvenile idiopathic arthritis (JIA) patients (11) . The MIF-173 C allele affect a potential activator protein 4 (AP-4) that may affect MIF expression (12, 13) . MIF levels are clearly high in patients with the MIF -173 C allele, so researchers compared levels of the G/C and C alleles in the serum and synovial fluid of JIA patients (14) . This research has supported that this can be predictive for the glucocorticoid treatment duration. Liu et al. (15) have examined the relationship between Chinese rheumatoid arthritis (RA) and MIF-173 polymorphism. They have not found a significant association between G/G, G/C and C/C genotype distributions whereas they have shown that the risk of RA disease is high in individuals who carry C/C genotype. In another study related to RA patients, it has been stated that C allele is related to the activity of RA disease (16) . It was have determined that the MIF -173 C is related to inflammatory sensitivity of polyarthritis whereas it is not in association with the intensity of the disease (17) . In another study, they have shown that particularly MIF -173 C allele leads to increased risk of early onset of RA disease (18) . MIF gene polymorphism is studied in many different inflammatory diseases. The association between the MIF -173 C/C genotype and predisposition to ulcerative colitis was also found on the Chinese people (19) . The C/C genotype is frequently seen in patients with pancolitis, although no genotype difference has been found to be associated with ulcerative colitis (20) . Przybylowska et al. (21) have shown that there is no difference between patients with respect to their genotypes in inflammatory bowel disease but MIF -173 G/C polymorphism C allele leads to increase in the risk of ulcerative colitis disease. HLA-B27 is an important indicator on AS progression (3). The rate of HLA-B27 varies in different studies in Turkey. Gunal et al. (22) and Cinar et al. (23) reported that the proportion of HLA-B27 positivity was 70.0% and 66.7%. Although HLA-B27 rate was lower than expected and determined as 32.3% on patients. Various genetic and environmental factors may contribute to the decreased HLA-B27 frequency observed among Turkish AS patients. Sample size also plays a role (22) .
It was determined that MIF polymorphisms may vary predictably for certain diseases, especially those related to the immune system. MIF-173 C allele and C/C genotype is high in asthmatic children (24) . Also, it was reported that MIF-173 C gene polymorphisms are positively associated to psoriasis (25) . MIF gene -173 C allele frequency is high in secondary sarcoidosis erythema nodosum patients (26) . Additionally, C allele and C/C genotype are highly seen in systemic lupus patients (27) . It was expressed that plasma MIF levels increase in Still's disease patients with C/C genotype (28) . Previous studies in children with Henoch-Schönlein purpura disease (29) and cutaneous vasculitis patients have shown that there is no genotype-phenotype association or C allele difference in these patients (30) .
In this study, we analyzed the relationship between AS disease, which is an inflammatory disease, and MIF polymorphism, which has a role in many inflammatory diseases. We have not determined the allele and genotype differences between AS patients and control group. We found a statistically significant difference in the average age of patients who carry the C allele and in the duration of disease. These findings show that the C allele can lead to early onset disease.
In conclusion, no previous study has examined the relationship between the AS disease and the MIF gene -173 G/C polymorphism in both Turkish. We have not found a relationship between AS disease and MIF -173 G/C polymorphism, but these results could change with further study if more patients and control samples are compared to each other with respect to age and gender. We have shown that the MIF -173 G/C polymorphism (C allele) can affect the time of onset and the duration of disease in AS patients.
